Protagenic Therapeutics (NASDAQ:PTIX) Faces Delisting Threat from NasdaqUnited States Securities and Exchange CommissionWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934Date of Report (

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Protagenic Therapeutics’s 8K filing here.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.